ZFIN ID: ZDB-PUB-150317-8
The cellular and molecular progression of mitochondrial dysfunction induced by 2,4-dinitrophenol in developing zebrafish embryos
Bestman, J.E., Stackley, K.D., Rahn, J.J., Williamson, T.J., Chan, S.S.
Date: 2015
Source: Differentiation; research in biological diversity   89(3-4): 51-69 (Journal)
Registered Authors: Chan, Sherine, Rahn, Jennifer, Stackley, Krista, Williamson, Tucker
Keywords: Embryo, Energy metabolism, In vivo respirometry, Motor neuron, Retina, Zebrafish
MeSH Terms:
  • 2,4-Dinitrophenol/toxicity
  • Adenosine Triphosphate/biosynthesis
  • Animals
  • Embryonic Development/genetics*
  • Energy Metabolism/genetics*
  • Gene Expression Regulation, Developmental/drug effects
  • Humans
  • Mitochondria/genetics*
  • Mitochondria/metabolism
  • Mitochondria/pathology
  • Mitochondrial Diseases/chemically induced
  • Mitochondrial Diseases/genetics*
  • Mitochondrial Diseases/metabolism
  • Mitochondrial Diseases/pathology
  • Motor Neurons/metabolism
  • Motor Neurons/pathology
  • Oxidative Phosphorylation/drug effects
  • Retina/metabolism
  • Retina/pathology
  • Zebrafish
PubMed: 25771346 Full text @ Differentiation
FIGURES
ABSTRACT
The etiology of mitochondrial disease is poorly understood. Furthermore, treatment options are limited, and diagnostic methods often lack the sensitivity to detect disease in its early stages. Disrupted oxidative phosphorylation (OXPHOS) that inhibits ATP production is a common phenotype of mitochondrial disorders that can be induced in zebrafish by exposure to 2,4-dinitrophenol (DNP), a FDA-banned weight-loss agent and EPA-regulated environmental toxicant, traditionally used in research labs as an uncoupler of OXPHOS. Despite the DNP-induced OXPHOS inhibition we observed using in vivo respirometry, the development of the DNP-treated and control zebrafish were largely similar during the first half of embryogenesis. During this period, DNP-treated embryos induced gene expression of mitochondrial and nuclear genes that stimulated the production of new mitochondria and increased glycolysis to yield normal levels of ATP. DNP-treated embryos were incapable of sustaining this mitochondrial biogenic response past mid-embryogenesis, as shown by significantly lowered ATP production and ATP levels, decreased gene expression, and the onset of developmental defects. Examining neural tissues commonly affected by mitochondrial disease, we found that DNP exposure also inhibited motor neuron axon arbor outgrowth and the proper formation of the retina. We observed and quantified the molecular and physiological progression of mitochondrial dysfunction during development with this new model of OXPHOS dysfunction, which has great potential for use in diagnostics and therapies for mitochondrial disease.
ADDITIONAL INFORMATION